A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence

Trial Profile

A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Luspatercept (Primary)
  • Indications Anaemia; Myelofibrosis
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 28 Aug 2017 Planned End Date changed from 7 Nov 2023 to 29 Jun 2019.
    • 18 Aug 2017 Planned initiation date changed from 20 Sep 2017 to 18 Oct 2017.
    • 03 Aug 2017 According to an Acceleron Pharma media release, the company expects to enroll the first patient in this trial by year end 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top